Jupiter Life Line Hospitals has recently been downgraded to a 'Hold' rating by MarketsMOJO. This decision comes despite the company's strong financial performance and growth potential.

Jupiter has achieved an impressive return on capital employed (ROCE) of 1,892.77% and a long-term growth rate of 33.71% in operating profit. In the past four quarters, the company has reported significant financial metrics, including a peak PBDIT of Rs 74.99 crore and net sales of Rs 322.58 crore.

The stock has a bullish technical outlook, supported by positive indicators such as MACD and KST. Institutional investors hold a substantial 25.71% stake in the company, indicating confidence in its fundamentals. Their holdings have increased by 2.38% in the last quarter.

Jupiter Life Line Hospitals has outperformed the BSE 500 index, achieving a return of 36.95% over the past year. However, its price-to-book ratio of 7.8 suggests that it may be overvalued. Despite a 40% rise in profits over the past year, the stock is currently considered expensive, leading to a cautious stance among investors.